Skip to content

Alterola Biotech, Inc.: 10-Q filed 2022-08-18

What Alterola Biotech, Inc. reported in its quarterly report filed 2022-08-18 (fiscal Q1 2023): 25 published measures, 55 facts as tagged in accession 0001663577-22-000478.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-18
Fiscal period
fiscal Q1 2023
Accession
0001663577-22-000478 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alterola Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-3012,119,360USD
At 2022-03-3112,127,961USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-301,228,010USD
At 2022-03-311,201,685USD
At 2021-05-28389,721USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-3010,891,350USD
At 2022-03-3110,926,276USD
At 2021-06-30-759,119USD
At 2021-01-06136USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-210,000USD91
2021-07-01 to 2022-03-31-6,471,134USD274
2021-04-01 to 2021-06-30-150,560USD91
2021-01-07 to 2021-06-30-343,033USD175

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-165,923USD91
2021-04-01 to 2021-06-30-718USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-04-01 to 2022-06-301,100USD91
2021-04-01 to 2021-06-30746USD91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-04-01 to 2021-06-300USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-8,180,510USD
At 2022-03-31-7,970,510USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-04-01 to 2022-06-30802,633,333shares91
2021-04-01 to 2021-06-30754,280,000shares91

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-04-01 to 2022-06-300USD/shares91
2021-04-01 to 2021-06-300USD/shares91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-210,000USD91
2021-04-01 to 2021-06-30-150,560USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-30119,360USD
At 2022-03-31127,691USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-301,076,397USD
At 2022-03-311,039,465USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-30570,509USD
At 2022-03-31542,510USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-04-01 to 2022-06-30210,000USD91
2021-04-01 to 2021-06-30150,560USD91

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2022-06-30969USD
At 2022-03-311,050USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-04-01 to 2022-06-3018,472USD91
2021-04-01 to 2021-06-30136,291USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-30802,633,333shares
At 2022-03-31802,633,333shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2022-06-3061,542USD
At 2022-03-3163,816USD
At 2021-06-30387USD
At 2021-03-31519USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-06-3018,079,554USD
At 2022-03-3118,079,554USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2022-06-30406,318USD
At 2022-03-31396,486USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2009-07-16 to 2022-03-31-8,180,510USD4642

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-3032,658USD91
2021-04-01 to 2021-06-305,158USD91

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-3037,867USD91
2021-04-01 to 2021-06-300USD91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-3027,999USD91
2021-04-01 to 2021-06-30240,151USD91

Inspect the source

Entity
Alterola Biotech, Inc. / CIK 0001442999
Captured
2026-09-21T17:19:50.475Z
SEC response SHA-256
87a3a16f9156f52960516ff7604a147caa80abebfe964591df0bd913491df844

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001442999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))